Variable course of Unverricht-Lundborg disease: Early prognostic factors

Neurology. 2017 Oct 17;89(16):1691-1697. doi: 10.1212/WNL.0000000000004518. Epub 2017 Sep 20.

Abstract

Objective: To explore the course of Unverricht-Lundborg disease (EPM1) and identify the risk factors for severity, we investigated the time course of symptoms and prognostic factors already detectable near to disease onset.

Methods: We retrospectively evaluated the features of 59 Italian patients carrying the CSTB expansion mutation, and coded the information every 5 years after the disease onset in order to describe the cumulative time-dependent probability of reaching disabling myoclonus, relevant cognitive impairment, and inability to work, and evaluated the influence of early factors using the log-rank test. The risk factors were included in a Cox multivariate proportional hazards regression model.

Results: Disabling myoclonus occurred an average of 32 years after disease onset, whereas cognitive impairment occurred a little later. An age at onset of less than 12 years, the severity of myoclonus at the time of first assessment, and seizure persistence more than 10 years after onset affected the timing of disabling myoclonus and cognitive decline. Most patients became unable to work years before the appearance of disabling myoclonus or cognitive decline.

Conclusions: A younger age at onset, early severe myoclonus, and seizure persistence are predictors of a more severe outcome. All of these factors may be genetically determined, but the greater hyperexcitability underlying more severe seizures and myoclonus at onset may also play a role by increasing cell damage due to reduced cystatin B activity.

MeSH terms

  • Adolescent
  • Adult
  • Age of Onset
  • Analysis of Variance
  • Anticonvulsants / therapeutic use
  • Cathepsin B / genetics
  • Electroencephalography
  • Evoked Potentials, Somatosensory / drug effects
  • Female
  • Humans
  • Italy
  • Male
  • Middle Aged
  • Phenytoin / therapeutic use
  • Prognosis
  • Retrospective Studies
  • Unverricht-Lundborg Syndrome / diagnosis*
  • Unverricht-Lundborg Syndrome / drug therapy
  • Unverricht-Lundborg Syndrome / genetics
  • Unverricht-Lundborg Syndrome / physiopathology*
  • Valproic Acid / therapeutic use
  • Young Adult

Substances

  • Anticonvulsants
  • Valproic Acid
  • Phenytoin
  • CTSB protein, human
  • Cathepsin B